메뉴 건너뛰기




Volumn 33, Issue 5, 2006, Pages 607-613

Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TEMSIROLIMUS;

EID: 33749642343     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.06.002     Document Type: Article
Times cited : (25)

References (52)
  • 2
    • 0345184913 scopus 로고    scopus 로고
    • Opportunities and challenges in the development of kinase inhibitor therapy for cancer
    • Sawyers C.L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17 (2003) 2998-3010
    • (2003) Genes Dev , vol.17 , pp. 2998-3010
    • Sawyers, C.L.1
  • 3
    • 1542398693 scopus 로고    scopus 로고
    • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    • Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
    • (2004) J Clin Oncol , vol.22 , pp. 909-918
    • Atkins, M.B.1    Hidalgo, M.2    Stadler, W.M.3
  • 4
    • 0036632368 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-kinase AKT pathway in human cancer
    • Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
    • (2002) Nat Rev Cancer , vol.2 , pp. 489-501
    • Vivanco, I.1    Sawyers, C.L.2
  • 5
    • 0031833563 scopus 로고    scopus 로고
    • Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
    • Abraham R.T. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 10 (1998) 330-336
    • (1998) Curr Opin Immunol , vol.10 , pp. 330-336
    • Abraham, R.T.1
  • 6
    • 0031755688 scopus 로고    scopus 로고
    • Studies on the mechanism of resistance to rapamycin in human cancer cells
    • Hosoi H., Dilling M.B., Liu L.N., et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54 (1998) 815-824
    • (1998) Mol Pharmacol , vol.54 , pp. 815-824
    • Hosoi, H.1    Dilling, M.B.2    Liu, L.N.3
  • 7
    • 0033557578 scopus 로고    scopus 로고
    • Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
    • Hosoi H., Dilling M.B., Shikata T., et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59 (1999) 886-894
    • (1999) Cancer Res , vol.59 , pp. 886-894
    • Hosoi, H.1    Dilling, M.B.2    Shikata, T.3
  • 8
    • 0038141979 scopus 로고    scopus 로고
    • Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
    • Zhang Y., Gao X., Saucedo L.J., et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5 (2003) 578-581
    • (2003) Nat Cell Biol , vol.5 , pp. 578-581
    • Zhang, Y.1    Gao, X.2    Saucedo, L.J.3
  • 9
    • 0036713778 scopus 로고    scopus 로고
    • TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
    • Inoki K., Li Y., Zhu T., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
    • (2002) Nat Cell Biol , vol.4 , pp. 648-657
    • Inoki, K.1    Li, Y.2    Zhu, T.3
  • 10
    • 30644468118 scopus 로고    scopus 로고
    • mTOR and cancer: Reason for dancing at the crossroads?
    • Thomas G.V. mTOR and cancer: Reason for dancing at the crossroads?. Curr Opin Genet Dev 16 (2006) 78-84
    • (2006) Curr Opin Genet Dev , vol.16 , pp. 78-84
    • Thomas, G.V.1
  • 11
    • 2342559981 scopus 로고    scopus 로고
    • The TOR pathway: A target for cancer therapy
    • Bjornsti M.A., and Houghton P.J. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
    • (2004) Nat Rev Cancer , vol.4 , pp. 335-348
    • Bjornsti, M.A.1    Houghton, P.J.2
  • 12
    • 0344063370 scopus 로고    scopus 로고
    • Will mTOR inhibitors make it as cancer drugs?
    • Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 4 (2003) 343-348
    • (2003) Cancer Cell , vol.4 , pp. 343-348
    • Sawyers, C.L.1
  • 13
    • 1642586272 scopus 로고    scopus 로고
    • Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
    • Wendel H.G., De Stanchina E., Fridman J.S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
    • (2004) Nature , vol.428 , pp. 332-337
    • Wendel, H.G.1    De Stanchina, E.2    Fridman, J.S.3
  • 14
    • 0013840905 scopus 로고
    • Tumour anoxia and the response to radiation
    • Thomlinson R. Tumour anoxia and the response to radiation. Sci Basis Med Annu Rev (1965) 74-90
    • (1965) Sci Basis Med Annu Rev , pp. 74-90
    • Thomlinson, R.1
  • 15
    • 84960987950 scopus 로고
    • The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
    • Gray L., Conger A., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
    • (1953) Br J Radiol , vol.26 , pp. 638-648
    • Gray, L.1    Conger, A.2    Ebert, M.3
  • 16
    • 0034321578 scopus 로고    scopus 로고
    • Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance
    • Vaupel P., and Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. Int J Oncol 17 (2000) 869-879
    • (2000) Int J Oncol , vol.17 , pp. 869-879
    • Vaupel, P.1    Hockel, M.2
  • 17
    • 0036359548 scopus 로고    scopus 로고
    • Hypoxia-A key regulatory factor in tumour growth
    • Harris A.L. Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
    • (2002) Nat Rev Cancer , vol.2 , pp. 38-47
    • Harris, A.L.1
  • 18
    • 0025951716 scopus 로고
    • Serial immunoreactive erythropoietin levels in autologous blood donors
    • Lorentz A., Jendrissek A., Eckardt K.U., et al. Serial immunoreactive erythropoietin levels in autologous blood donors. Transfusion 31 (1991) 650-654
    • (1991) Transfusion , vol.31 , pp. 650-654
    • Lorentz, A.1    Jendrissek, A.2    Eckardt, K.U.3
  • 19
    • 0036216692 scopus 로고    scopus 로고
    • HIF-1 and tumor progression: Pathophysiology and therapeutics
    • Semenza G.L. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 8 (2002) S62-S67
    • (2002) Trends Mol Med , vol.8
    • Semenza, G.L.1
  • 20
    • 0035012605 scopus 로고    scopus 로고
    • HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
    • Laughner E., Taghavi P., Chiles K., et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
    • (2001) Mol Cell Biol , vol.21 , pp. 3995-4004
    • Laughner, E.1    Taghavi, P.2    Chiles, K.3
  • 21
    • 0035503362 scopus 로고    scopus 로고
    • Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer
    • Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61 (2001) 7992-7998
    • (2001) Cancer Res , vol.61 , pp. 7992-7998
    • Giatromanolaki, A.1    Koukourakis, M.I.2    Sivridis, E.3
  • 22
    • 0034654174 scopus 로고    scopus 로고
    • Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
    • Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
    • (2000) Cancer Res , vol.60 , pp. 1541-1545
    • Zhong, H.1    Chiles, K.2    Feldser, D.3
  • 23
    • 0033571682 scopus 로고    scopus 로고
    • Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
    • Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
    • (1999) Cancer Res , vol.59 , pp. 5830-5835
    • Zhong, H.1    De Marzo, A.M.2    Laughner, E.3
  • 24
    • 0034654174 scopus 로고    scopus 로고
    • Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
    • Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
    • (2000) Cancer Res , vol.60 , pp. 1541-1545
    • Zhong, H.1    Chiles, K.2    Feldser, D.3
  • 25
    • 0034050050 scopus 로고    scopus 로고
    • Loss of PTEN facilitates HIF-1-mediated gene expression
    • Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
    • (2000) Genes Dev , vol.14 , pp. 391-396
    • Zundel, W.1    Schindler, C.2    Haas-Kogan, D.3
  • 26
    • 0034925041 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1
    • Jiang B.H., Jiang G., Zheng J.Z., et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12 (2001) 363-369
    • (2001) Cell Growth Differ , vol.12 , pp. 363-369
    • Jiang, B.H.1    Jiang, G.2    Zheng, J.Z.3
  • 27
    • 0142166332 scopus 로고    scopus 로고
    • Targeting HIF-1 for cancer therapy
    • Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
    • (2003) Nat Rev Cancer , vol.3 , pp. 721-732
    • Semenza, G.L.1
  • 28
    • 0041920901 scopus 로고    scopus 로고
    • TSC2 regulates VEGF through mTOR-dependent and -independent pathways
    • Brugarolas J.B., Vazquez F., Reddy A., et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
    • (2003) Cancer Cell , vol.4 , pp. 147-158
    • Brugarolas, J.B.1    Vazquez, F.2    Reddy, A.3
  • 29
    • 0036718539 scopus 로고    scopus 로고
    • Molecular basis of the VHL hereditary cancer syndrome
    • Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
    • (2002) Nat Rev Cancer , vol.2 , pp. 673-682
    • Kaelin, W.G.1
  • 30
    • 0027238288 scopus 로고
    • Molecular genetic studies of sporadic and familial renal cell carcinoma
    • Gnarra J.R., Glenn G.M., Latif F., et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 20 (1993) 207-216
    • (1993) Urol Clin North Am , vol.20 , pp. 207-216
    • Gnarra, J.R.1    Glenn, G.M.2    Latif, F.3
  • 31
    • 0027954044 scopus 로고
    • Mutations of the VHL tumour suppressor gene in renal carcinoma
    • Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
    • (1994) Nat Genet , vol.7 , pp. 85-90
    • Gnarra, J.R.1    Tory, K.2    Weng, Y.3
  • 32
    • 0028072991 scopus 로고
    • Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
    • Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 (1994) 9700-9704
    • (1994) Proc Natl Acad Sci U S A , vol.91 , pp. 9700-9704
    • Herman, J.G.1    Latif, F.2    Weng, Y.3
  • 33
    • 0033587146 scopus 로고    scopus 로고
    • The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
    • Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
    • (1999) Nature , vol.399 , pp. 271-275
    • Maxwell, P.H.1    Wiesener, M.S.2    Chang, G.W.3
  • 34
    • 0033776536 scopus 로고    scopus 로고
    • Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein
    • Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 (2000) 423-427
    • (2000) Nat Cell Biol , vol.2 , pp. 423-427
    • Ohh, M.1    Park, C.W.2    Ivan, M.3
  • 35
    • 0036527785 scopus 로고    scopus 로고
    • The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma
    • Maranchie J.K., Vasselli J.R., Riss J., et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
    • (2002) Cancer Cell , vol.1 , pp. 247-255
    • Maranchie, J.K.1    Vasselli, J.R.2    Riss, J.3
  • 36
    • 0036528246 scopus 로고    scopus 로고
    • Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
    • Kondo K., Klco J., Nakamura E., et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
    • (2002) Cancer Cell , vol.1 , pp. 237-246
    • Kondo, K.1    Klco, J.2    Nakamura, E.3
  • 37
    • 0035312747 scopus 로고    scopus 로고
    • Regulation of translation initiation by FRAP/mTOR
    • Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15 (2001) 807-826
    • (2001) Genes Dev , vol.15 , pp. 807-826
    • Gingras, A.C.1    Raught, B.2    Sonenberg, N.3
  • 38
    • 0035233058 scopus 로고    scopus 로고
    • Control of translation by the target of rapamycin proteins
    • Gingras A.C., Raught B., and Sonenberg N. Control of translation by the target of rapamycin proteins. Prog Mol Subcell Biol 27 (2001) 143-174
    • (2001) Prog Mol Subcell Biol , vol.27 , pp. 143-174
    • Gingras, A.C.1    Raught, B.2    Sonenberg, N.3
  • 39
    • 0000183432 scopus 로고    scopus 로고
    • CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study
    • (abstr)
    • Hidalgo M., Rowinsky E., Erlichman C., et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study. Proc Am Soc Clin Oncol 19 (2000) 726A (abstr)
    • (2000) Proc Am Soc Clin Oncol , vol.19
    • Hidalgo, M.1    Rowinsky, E.2    Erlichman, C.3
  • 41
    • 9144233506 scopus 로고    scopus 로고
    • Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
    • Bouley A., Zumstein S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 (2004) 252-261
    • (2004) Cancer Res , vol.64 , pp. 252-261
    • Bouley, A.1    Zumstein, S.2    Stephan, C.3
  • 42
    • 29244459713 scopus 로고    scopus 로고
    • Mammalian target of rapamycin as a therapeutic target in leukemia
    • Giles F.J., and Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 5 (2005) 653-661
    • (2005) Curr Mol Med , vol.5 , pp. 653-661
    • Giles, F.J.1    Albitar, M.2
  • 43
    • 27644447574 scopus 로고    scopus 로고
    • The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy
    • Jonas A., Robak T., and Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10 (2005) 479-498
    • (2005) Cell Mol Biol Lett , vol.10 , pp. 479-498
    • Jonas, A.1    Robak, T.2    Smolewski, P.3
  • 44
    • 11344271046 scopus 로고    scopus 로고
    • Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer
    • Boni J.P., Leister C., Bender G., et al. Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77 (2005) 76-89
    • (2005) Clin Pharmacol Ther , vol.77 , pp. 76-89
    • Boni, J.P.1    Leister, C.2    Bender, G.3
  • 45
    • 0003166055 scopus 로고    scopus 로고
    • CCI-779, a rapamycin analogue with antitumor activity: A phase I study utilizing a weekly schedule
    • (abstr)
    • Raymond E., Alexandre J., Depenbrock H., et al. CCI-779, a rapamycin analogue with antitumor activity: A phase I study utilizing a weekly schedule. Proc Am Soc Clin Oncol 19 (2000) 187a (abstr)
    • (2000) Proc Am Soc Clin Oncol , vol.19
    • Raymond, E.1    Alexandre, J.2    Depenbrock, H.3
  • 46
    • 8344281974 scopus 로고    scopus 로고
    • Targeting the molecular target of rapamycin (mTOR)
    • Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16 (2004) 564-575
    • (2004) Curr Opin Oncol , vol.16 , pp. 564-575
    • Rowinsky, E.K.1
  • 48
    • 17944377486 scopus 로고    scopus 로고
    • Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
    • Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98 (2001) 10314-10319
    • (2001) Proc Natl Acad Sci U S A , vol.98 , pp. 10314-10319
    • Neshat, M.S.1    Mellinghoff, I.K.2    Tran, C.3
  • 49
    • 0038615946 scopus 로고    scopus 로고
    • Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo
    • Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 (2003) 2742-2746
    • (2003) Cancer Res , vol.63 , pp. 2742-2746
    • Choe, G.1    Horvath, S.2    Cloughesy, T.F.3
  • 50
    • 19944427667 scopus 로고    scopus 로고
    • Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer
    • Thomas G.V., Horvath S., Smith B.L., et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 10 (2004) 8351-8356
    • (2004) Clin Cancer Res , vol.10 , pp. 8351-8356
    • Thomas, G.V.1    Horvath, S.2    Smith, B.L.3
  • 51
    • 24144481478 scopus 로고    scopus 로고
    • Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway
    • (abstr)
    • Pantuck A.J., Seligson D., Wu H., et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Urol 173 (2005) 96a (abstr)
    • (2005) J Urol , vol.173
    • Pantuck, A.J.1    Seligson, D.2    Wu, H.3
  • 52
    • 30044432434 scopus 로고    scopus 로고
    • Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
    • Thomas G.V., Tran C., Mellinghof I., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122
    • (2006) Nat Med , vol.12 , pp. 122
    • Thomas, G.V.1    Tran, C.2    Mellinghof, I.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.